Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AxSpA patient populations covering 171 countries and more than 99%…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of hospital-treated gram-negative infections (HT-GNIs) comprises epidemiological estimates of nine types of infections: urinary tract infections, bloodstream…
Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…
Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report…
Clarivate Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report…
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…